The Rise Of Medicinal Approaches Opens New Avenues For The Menstrual Cramps Treatment Market
The menstrual cramps treatment market is estimated to be valued at US$ 652.3 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Menstrual cramps, also known as dysmenorrhea, are usually caused by an imbalance of prostaglandins and leukotrienes that leads to contractions in the uterus. Some common symptoms include lower abdominal pain, backaches, headaches, and nausea. Medication for menstrual cramp treatment aims to block or reduce prostaglandin production through oral contraceptives, nonsteroidal anti-inflammatory drugs (NSAIDs), and other prescription medications. Physical therapy approaches like heat therapy and massage are also used.
Market Dynamics:
The growth of the menstrual cramps treatment market is driven by the rise in awareness about various treatment options and increasing preference for medication over invasive procedures. According to the U.S. Department of Health and Human Services, around 90% of women suffer from menstrual cramps at some point. However, only 50% seek treatment due to the social stigma surrounding periods and menstrual health issues. Educational campaigns by non-profits are increasing awareness about menstrual cramps being a common issue with effective treatment available. This is helping to normalize the discussion around periods and encouraging more women to seek medical help for cramps. Furthermore, the availability of over-the-counter NSAID medications and apps that help track menstrual cycles have made self-treatment more accessible and convenient. This is contributing to the growth of the menstrual cramps treatment market.
Segment Analysis
The global menstrual cramps treatment market is dominated by over-the-counter (OTC) medications segment. This segment currently holds around 60% of the total market share owing to high adoption of cheaper and easily available pain relief drugs for minor to moderate menstrual cramps. However, the prescription drugs segment is expected to witness fastest growth during the forecast period. Increasing awareness about various prescription pain relievers as well as rising availability of generics are some of the key factors likely to boost the growth of prescription drugs segment over the coming years.
PEST Analysis
Political: The government policies supporting women healthcare is promoting adoption of advanced treatment drugs and devices in many countries. However, lack of awareness in some under developed regions hinders market growth.
Economic: Rising spending on women health and increasing disposable income levels globally are positive factors for market growth. Additionally, healthcare reforms in emerging nations is supporting market expansion.
Social: Open social discussions on women issues and removing stigma related to menstruation has increased acceptance of various treatment options, thus supporting market demand.
Technological: Advancements in drug delivery systems and devices used for pain management are allowing development of more effective therapeutics. This is positively impacting the market growth.
Key Takeaways
The Global Menstrual Cramps Treatment Market Growth is expected to witness high, exhibiting CAGR of 4.4% over the forecast period, due to increasing awareness about various treatment options and availability of generics.
The global market size for menstrual cramps treatment was valued at US$ 652.3 Mn in 2023 and is expected to reach over US$ 1 Bn by 2030.
Regional analysis: North America dominated the global market and held over 40% share in 2023 owing to rising awareness, favorable reimbursement policies and presence of major players in the region. Asia Pacific is likely to witness fastest growth during the forecast period attributed to increasing healthcare expenditure, growing women population and rising disposable incomes.
Key players operating in the menstrual cramps treatment market are Stryker Corporation, SATELEC (Actongroup), Surgiform Innovative Surgical Products, Allergan (Abbvie) Luminera, Implantech, Koken, ANTHONY PRODUCTS INC., NOUVAG, Sihuan Pharmaceutical Holdings Group Ltd., and Other prominent players. Stryker Corporation is one of the leading player with wide product portfolio and global presence.